News/ News/ R&D Quench targets lupus and rare diseases with R&D into new drug class Richard Staines AbbVie, inflamatory diseases, Quench Bio, R&D 0 Comment Quench Bio has emerged from stealth mode with $50 million of committed funding, bidding to be the first Share X Quench targets lupus and rare diseases with R&D into new drug class https://pharmaphorum.com/news/uk-biotech-targets/
